Program
VRN110755
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Voronoi.
Furthest: phase 2, since Jul 1, 20262 company-led studies, 1 open or runningNext primary completion: Jan 1, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Voronoi | 21 open or running | phase 2since Jul 1, 2026 | Jul 24, 2025 | Jan 1, 2029phase 2 · NCT07699328 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2025First study: phase 1 study in HealthyFirst studyNCT07141381 · 25 enrolled · Australia
- Jul 1, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07699328 · 315 planned · Australia, Canada, France and more
Ahead
- Jan 1, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07699328
TargetBeta
EGFR →read by rule
“This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-sm…”study text, by rule · the study
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07699328Carcinoma, Non-Small-Cell Lung · Australia, Canada, France and more | 2 | Recruiting | Jan 1, 2029 | 315 |
| NCT07141381Healthy · Australia | 1 | Completed | Dec 17, 2025 | 25 |
How it is read
Names in the registry
- “VRN110755”, 2 entries
Codes read as this program: VRN110755.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.